Current cannabis use and tardive dyskinesia

Area of Science:

• Psychiatry
• Neuroscience
• Pharmacology

Background:

• Tardive dyskinesia (TD) is a serious side effect of long-term neuroleptic treatment.
• Factors contributing to TD development in schizophrenia patients are not fully understood.
• Substance abuse is a potential, yet under-researched, risk factor for TD.

Purpose of the Study:

• To investigate the association between substance abuse and tardive dyskinesia (TD) in schizophrenia patients.
• To identify which substance use patterns correlate most strongly with TD.
• To explore the role of other factors like smoking, caffeine, and neuroleptic dose in TD development.

Main Methods:

• A cohort of 51 chronic, neuroleptic-treated schizophrenia outpatients was studied.
• Data collected included substance use history (alcohol, cannabis, drugs), smoking, caffeine intake, and current neuroleptic dose.
• Abnormal Involuntary Movement Scale (AIMS) was administered by trained raters to assess TD severity.

Main Results:

• A trend for higher AIMS scores was observed in females and older patients with longer illness duration.
• Hierarchical multiple regression analysis identified cannabis use as the strongest predictor of TD.
• Cannabis use significantly outranked other investigated factors, including neuroleptic dose and illness duration, in its correlation with TD.

Conclusions:

• Cannabis use is a significant correlate of tardive dyskinesia in schizophrenia patients on long-term neuroleptic treatment.
• Clinicians should consider substance abuse, particularly cannabis use, when assessing TD risk.
• Further research is warranted to elucidate the neurobiological mechanisms linking cannabis and TD.